Annovis Publishes Phase 2/3 AD Data in Nature; Phase 3 Enrollment Hits 80%

What happened

Annovis Bio published its Phase 2/3 Alzheimer's trial results for buntanetap in the peer-reviewed journal Nature NPJ Dementia, showing improved cognition in pTau217-positive early AD patients and reductions in neurotoxic proteins and biomarkers of neuroinflammation and neurodegeneration. The drug was safe and well-tolerated, including in ApoE4 carriers, supporting the ongoing Phase 3 pivotal trial, which now reports 80% enrollment—a notable acceleration from the ~25% enrollment reported in late 2025. While the publication provides external validation of the drug's mechanism and earlier positive subgroup data, the DeepValue report has maintained a WAIT rating due to significant financing risk, with cash only sufficient through Q3 2026 and an explicit going-concern warning. The news does not resolve the key near-term overhang: Annovis must still raise additional capital to complete the Phase 3 trial and reach its H2 2026/H2 2027 data readouts, and any future financing could be highly dilutive given the current market cap of ~$63M. The improved enrollment momentum reduces one operational risk but does not eliminate the funding cliff, meaning the stock remains a high-risk binary option on Phase 3 data, with the publication serving more as scientific de-risking than financial de-risking.

Implication

Investors should view the Nature publication as positive scientific validation that modestly bolsters the probability of success for buntanetap. However, the core investment thesis remains driven by the company's ability to secure non-punitive funding to reach Phase 3 readouts. The improved enrollment to 80% is a positive operational signal but does not change the need for substantial capital. Given the WAIT rating and bearish financing scenarios, the risk-reward is skewed to the downside in the near term unless clear funding de-risking occurs.

Thesis delta

The Nature publication and 80% enrollment update represent positive scientific and operational signals that reduce some uncertainty around buntanetap's efficacy and trial feasibility. However, these do not alter the central thesis that Annovis's near-term equity returns are dominated by financing risk and dilution. The WAIT rating remains appropriate as the funding cliff still looms, and the new data are incremental rather than transformative for the investment case.